MEI Pharma, a U.S.-based biotechnology firm, has made headlines by announcing the launch of a $100 million Litecoin (LTC) Treasury Strategy, becoming the first publicly traded company to adopt Litecoin as its primary reserve asset. This groundbreaking shift blends traditional biotech with the forward momentum of digital finance.
$100 Million PIPE Deal
The company entered into a definitive agreement to raise approximately $100 million through a Private Investment in Public Equity (PIPE) deal. The offering includes roughly 29.24 million common shares (or pre-funded warrants) at a price of $3.42 per share. All net proceeds will be used exclusively to purchase Litecoin, establishing a long-term crypto-backed financial reserve.
Charlie Lee Joins the Board
In a strategic and symbolic move, Charlie Lee, the creator of Litecoin, will join MEI Pharma’s Board of Directors following the closing of the financing. He replaces outgoing board member Taheer Datoo.
Lee expressed enthusiasm about the decision, noting that Litecoin’s core principles—speed, security, and decentralization—align well with corporate treasury needs in the modern economy. His presence is expected to boost both investor confidence and internal strategic direction.
Strategic Oversight by GSR
The company’s Litecoin treasury operations will be managed by GSR, a leading digital asset manager and market-maker. GSR will provide guidance on treasury implementation, asset custody, and regulatory compliance, ensuring a professional and secure process.
Institutional Support
MEI’s bold direction is supported by several notable institutional investors, including the Litecoin Foundation, MOZAYYX, ParaFi, Hivemind, CoinFund, Delta Blockchain, Primitive, and RLH Capital. Their participation reinforces the legitimacy and potential of integrating cryptocurrency into public company treasuries.
Market Impact
Following the announcement, MEI Pharma’s stock surged by over 100%, reflecting investor optimism and strong market demand for innovation at the intersection of biotech and crypto. This move sets a new precedent that may encourage other companies to explore similar strategies.
What's Next?
-
The financing is expected to close on or about July 22, 2025, subject to customary closing conditions.
-
Following the close, MEI Pharma will file a resale registration statement with the SEC for the newly issued shares.
The company is expected to begin acquiring Litecoin shortly thereafter.